EP2788001

NASAL FORMULATION

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    4.12.2012
  • EP published:
    2.12.2015
  • EP application number:
    12797884.9
  • Max expiry date:
    3.12.2032
  • Title:
    NASAL FORMULATION

Timeline

Today
4.12.2012EP application
2.12.2015EP Publication

Owner

  • Name:
    Teva Branded Pharmaceutical Products R & D, Inc.
  • Address:
    41 Moores Road, 19355, Frazer, Pennsylvania, US

Inventor

  • Name:
    ZENG, Xian-Ming
  • Address:
    Miami, Florida, US
  • Name:
    LY, Jade Ching-Ying
  • Address:
    Miami, Florida, US
  • Name:
    DALVI, Mukul C
  • Address:
    Miami, Florida, US

Priority

  • Number:
    201161567893 P
  • Date:
    7.12.2011
  • Country:
    US
  • Number:
    201121812
  • Date:
    19.12.2011
  • Country:
    GB

Classification

  • Categories:
    A61K 31/55, A61K 31/573, A61K 9/00, A61K 9/12, A61M 11/04, A61M 11/06, A61M 15/00, A61M 15/08, A61P 27/14

Upload documents